Vir Biotechnology Inc

Despite the long-term downtrend, the stock is in a high-confidence Stage 2 advance with clear higher highs and lows, supported by rising EMAs and bullish patterns. An active Lockout Rally override makes short-term execution favorable now, as price holds above the 9/21 EMA zone. We will buy into shallow pullbacks around the EMAs, aiming to participate in continuation under a speculative framework.

• ↑Cash $809.3M runway supports R&D through mid-2028.
• ↑Astellas partnership worth $1.7B accelerates VIR5500 development and profits.
• ↓Q1 net loss $125.7M reflects sustained high R&D burn.